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S U M M A R Y
The classiﬁcation of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an
appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB
cases that do not fulﬁl the criteria for the shorter MDR-TB regimen. The World Health Organization
(WHO) has recently approved a revision of the classiﬁcation of new anti-TB drugs based on current
evidence on each drug. In the previous WHO guidelines, the choice of drugs was based on efﬁcacy and
toxicity in a step-down manner, from group 1 ﬁrst-line drugs and groups 2–5 second-line drugs, to group
5 drugs with potentially limited efﬁcacy or limited clinical evidence. In the revised WHO classiﬁcation,
exclusively aimed at managing drug-resistant cases, medicines are again listed in hierarchical order from
group A to group D. In parallel, a possible future classiﬁcation is independently proposed. The aim of this
viewpoint article is to describe the evolution in WHO TB classiﬁcation (taking into account an
independently proposed new classiﬁcation) and recent changes in WHO guidance, while commenting on
the differences between them. The latest evidence on the ex-group 5 drugs is also discussed.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The World Health Organization (WHO) has recently updated
the classiﬁcation of new anti-tuberculosis (TB) drugs based on a
meta-analysis and expert panel recommendations.1 During the
period between the publication of the ﬁrst WHO anti-TB drug
classiﬁcation and the revised version, an independent proposal
for a new classiﬁcation was made available in the literature.2
Evidence for further reclassiﬁcation is lacking and will only be
forthcoming with data from new randomized controlled trials* Corresponding author. Tel.: +39 0331829404.
E-mail address: giovannibattista.migliori@fsm.it (G.B. Migliori).
Please cite this article in press as: Tiberi S, et al. Classifying new anti-
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.10.026
http://dx.doi.org/10.1016/j.ijid.2016.10.026
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(RCTs) aimed at developing better (more effective and tolerated)
regimens. However, even though a new classiﬁcation is not
required, discussion on possible future steps has begun,2 with
particular focus on some of the existing second-line anti-TB
drugs.
The classiﬁcation of anti-TB drugs is important as it helps the
clinician to build an appropriate anti-TB regimen for multidrug-
resistant (MDR) and extensively drug-resistant (XDR) TB cases that
do not fulﬁl the criteria for the shorter MDR-TB regimen.3,4
The aim of this viewpoint article is to describe the evolution in
WHO TB classiﬁcation (taking into account an independently
proposed new classiﬁcation) and recent changes in WHO guidance,
while commenting on the differences between them. The latest
evidence on the ex-group 5 drugs is also discussed.tuberculosis drugs: rationale and future perspectives. Int J Infect
ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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In the previous WHO guidelines (2011), the choice of drugs was
based on efﬁcacy and toxicity in a step-down manner, from group
1 to group 5 (Table 1). Group 1 included ﬁrst-line drugs and groups
2–5 included second-line drugs. Group 5 included the drugs with
(at the time) potentially limited efﬁcacy or limited clinical
evidence.3,4
According to the new WHO drug classiﬁcation (2016), patients
with rifampicin-resistant or MDR-TB require a regimen with at
least ﬁve effective TB medicines during the intensive phase:
pyrazinamide and four core second-line TB drugs (see Table 1), one
each from group A and group B, and at least two from group C. If the
minimum number of effective TB medicines cannot be composed,
an agent from group D2 and other agents from D3 should be added
to bring the total to ﬁve. If pyrazinamide is compromised or cannot
be used, the regimen can be reinforced with a drug from group C or
D (preferably D2, and if not, from D3). Agents from group D1 are
added if they are considered to add beneﬁt (e.g., high-dose
isoniazid in patients without high-level isoniazid resistance).1 The
total number of TB medicines included in the regimen needs to
balance the expected beneﬁt with the risk of harm and non-
adherence.
Based on recent evidence on given compounds, some drugs are
likely to increase or decrease in importance in the future.2
2.1. Group 1
In accordance with drug susceptibility testing (DST), all active
group 1 drugs (Table 1) should be included in the regimen, taking
into consideration that isoniazid, rifampicin/rifabutin, and pyr-
azinamide are core drugs and ethambutol is a companion drug.
Streptomycin is no longer used routinely.Table 1
Summary of the existing classiﬁcations of anti-tuberculosis drugs (1 and 2) and possib
(1) WHO 2011 TB drugs classiﬁcation (2) WHO 2016 TB 
Group 1
First-line oral anti-TB drugs
 Isoniazid
 Rifampicin
 Ethambutol
 Pyrazinamide
Group A
Fluoroquinolones
Group 2
Injectable anti-TB drugs
(injectable or parenteral agents)
 Streptomycin
 Kanamycin
 Amikacin
 Capreomycin
Group B
Second-line
injectable
agents
Group 3
Fluoroquinolones
 Levoﬂoxacin
 Moxiﬂoxacin
 Gatiﬂoxacin
 Oﬂoxacin
Group C
Other core
second-line
agents
Group 4
Oral bacteriostatic second-line
anti-TB drugs
 Ethionamide/
prothionamide
 Cycloserine/terizidone
 p-Aminosalicylic acid
Group D
Add-on agents
(not core MDR-TB
regimen
components)Group 5
Anti-TB drugs with limited data
on efﬁcacy and long-term
safety in the treatment of
drug-resistant TB
 Linezolid
 Clofazimine
 Amoxicillin/
clavulanate
 Imipenem/cilastatin
 Meropenem
 High-dose isoniazid
 Thioacetazone
 Clarithromycin
WHO, World Health Organization; MDR-TB, multidrug-resistant tuberculosis.
Please cite this article in press as: Tiberi S, et al. Classifying new anti-
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.10.026High-dose isoniazid can be added to an MDR/XDR-TB regimen
when the katG mutation is not detected by line probe assay, but
should not be counted as one of the four active drugs1,3,4 (although
recent evidence suggests the mutation confers intermediate
resistance only). Pyrazinamide should always be used, as DST is
unreliable; however, it should not be counted as one of the four
active drugs.1,3,4 Rifabutin should be considered if sensitivity is
proven and a favourable mutation proﬁle exists.5 More speciﬁcally,
if rifampicin resistance is detected with rifabutin susceptibility,
rifabutin should be added to the regimen, but not counted as one of
the four active drugs.5
As the new WHO classiﬁcation is aimed at managing drug-
resistant cases and not all cases, as in the previous classiﬁcation,
group 1 drugs lose priority. In the new WHO classiﬁcation they
belong, in fact, to group D1.
2.2. Group A
According to the new WHO classiﬁcation,1 group A now
includes ﬂuoroquinolones and group B includes injectable second-
line drugs. Fluoroquinolones (particularly the later generation
ﬂuoroquinolones such as high-dose levoﬂoxacin, gatiﬂoxacin, or
moxiﬂoxacin) are core drugs, demonstrating bactericidal and
sterilizing activity and a good safety proﬁle;2,3,6,7 their use predicts
a favourable outcome in the treatment of MDR-TB.7–11 They are the
best agents for the treatment of MDR-TB.
2.3. Group B
The second-line injectable drugs have only bactericidal and no
sterilizing activity. As their safety proﬁle is clearly worse than that
of ﬂuoroquinolones, they remain a step below them on the
ranking.2,4,6le future changes based on recent evidence (3)
drugs classiﬁcation (3) Possible future evolutions
 Levoﬂoxacin
 Moxiﬂoxacin
 Gatiﬂoxacin
Group A
Fluoroquinolones
 Levoﬂoxacin
 Moxiﬂoxacin
 Gatiﬂoxacin
 Amikacin
 Capreomycin
 Kanamycin
(Streptomycin)
Group B
Other core
second-line
agents
 Bedaquiline
 Delamanid
 Ethionamide/
prothionamide
 Cycloserine/
terizidone
 Linezolid
 Clofazimine
 Ethionamide/
prothionamide
 Cycloserine/
terizidone
 Linezolid
 Clofazimine
Group C
Second-line
injectable
agents
 Amikacin
 Capreomycin
 Kanamycin
 Meropenem/
clavulanate
D1  Pyrazinamide
 Ethambutol
 High-dose isoniazid
Group D
Add-on agents
(not core MDR-TB
regimen
components)
 Pyrazinamide
 Ethambutol
 High-dose
isoniazid
 p-Aminosalicylic
acid
 Amoxicillin–
clavulanate
 Rifabutin
D2  Bedaquiline
 Delamanid
D3  p-Aminosalicylic acid
 Imipenem–cilastatin
 Meropenem
 Amoxicillin–clavulanate
 (Thioacetazone)
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may in future include three core oral medicines, linezolid,
bedaquiline, and delamanid (and eventually sutezolid, tedizolid,
and pretomanid), if these drugs prove to be more effective and
better tolerated than the injectables.2 This has been proposed in a
recent article as group 3 (similar to the current group B, because in
this article group 1 is composed of ﬁrst-line drugs).2
Moreover, having an oral group B could mean that it may soon
be possible to have an injectable-free regimen to treat MDR-TB
patients; this will mean potentially less toxicity, less monitoring,
and fewer hospital stays and visits, and possibly better adherence.
2.4. Group C
Linezolid, clofazimine, ethionamide/prothionamide, and cyclo-
serine/terizidone are included in group C. Linezolid is a core oral
drug with bactericidal and sterilizing action;2 there is ample
evidence of its efﬁcacy, including RCTs and meta-analyses.12,13 The
drug is generic and active, its documented toxicity being the
primary barrier to continued use. However, this can be mitigated
with lower doses and therapeutic drug monitoring.13,14 Linezolid
has the efﬁcacy needed to be part of a future hypothetical all-oral
group B. With effectiveness in mind, the second drug in this group
could be ethionamide/prothionamide, which has moderate bac-
tericidal activity but with an appreciable toxicity proﬁle.4 The third
agent could be clofazimine, as this has possible sterilizing activity
and good tolerance. The last one could be cycloserine, the worst of
the four, with practically no bactericidal or sterilizing activity and
with a poor toxicity proﬁle.2,4
2.5. Group D
Group D1 includes pyrazinamide, ethambutol, and high-dose
isoniazid. Group D2 includes bedaquiline and delamanid. These
may have the efﬁcacy needed to be part of a future hypothetical all-
oral group B, given that evidence on their safety is growing,
although it is still incomplete. Data regarding their safe combina-
tion and whole treatment duration over the recommended
6 months are gradually emerging.
Recent case reports show the safe and effective use of
bedaquiline up to 18 months15 and the concomitant use of both
group D2 drugs.16 Bedaquiline has all of the characteristics of a
core drug, targeting both actively replicating and dormant bacilli.17
RCTs provide some evidence on efﬁcacy and safety,18,19 while
additional experience derived from observational studies and
compassionate use programmes completes the current pic-
ture.15,20–22 Concerns regarding the safety of bedaquiline arose
from the unexplained higher number of deaths in the bedaquiline
group in a licensing study.18
The most common adverse reaction associated with bedaqui-
line is a QTc interval increase on electrocardiogram.18,19 An RCT
with long-term follow-up to 120 weeks reported that bedaquiline
was well tolerated and led to good outcomes.20 The reporting of
adverse events is crucial for recommendations on bedaquiline
use;23 therefore monitoring, active pharmacovigilance, and proper
management of adverse reactions are foremost among the ﬁve
criteria in place for the use of this agent. Finally, a possible issue is
cross-resistance with clofazimine24 (although recent evidence
tends to suggest that this may not be clinically relevant) and the
increased QT prolongation with clofazimine and bedaquiline
combination (which appears to be a causative factor leading to
increased QTc in previous bedaquiline studies).25
Delamanid can also be considered a core drug because of its
bactericidal and sterilizing activity; it does not show cross-
resistance with other anti-TB drugs.26 Some RCTs and observa-
tional studies have addressed its efﬁcacy,26 and there are also somePlease cite this article in press as: Tiberi S, et al. Classifying new anti-
Dis (2017), http://dx.doi.org/10.1016/j.ijid.2016.10.026positive experiences from its compassionate use.26 WHO recom-
mendations on delamanid use27 include the same ﬁve implemen-
tation criteria as in the case of bedaquiline.23
As mentioned above, a signiﬁcant limitation of bedaquiline and
delamanid use is that, so far, they can be utilized only for the ﬁrst
6 months of treatment. When treating XDR-TB patients, these
drugs are added to an optimized background regimen that often
includes weak and poorly tolerated medications (from the limited
options remaining), with severe side effects mandating interrup-
tion of either the whole treatment or of the offending compound.
When this happens, the regimen becomes even weaker and, once
bedaquiline or delamanid is completed after 6 months, the
regimen is prone to fail.
The possibility of maintaining bedaquiline and/or delamanid
for the entire duration of treatment will be an important step
forward, as well as their use in patients with MDR-TB patterns of
resistance beyond XDR-TB,10 or the so-called pre-XDR-TB (e.g., TB
sustained by strains resistant to either ﬂuoroquinolones or second-
line injectables).2,15,16
After the proposed reclassiﬁcation of groups 2 and 3 to group B
and group A, respectively, the injectable second-line drugs might
have the characteristics of a future group C, as recently suggested
(Table 1).2
Indeed, they remain core second-line drugs thanks to their
bactericidal activity, but given their cumulative toxicity (4–8
months of treatment increases the likelihood of ototoxicity or
nephrotoxicity) and the requirement for parenteral or intramus-
cular administration, they would rank lower than the previously
described compounds.2 Although experience is still limited,
meropenem/clavulanate has demonstrated efﬁcacy and is
bactericidal. A recent phase 2 study28 and observational
studies29 compel us to consider meropenem/clavulanate a core
drug at the same level as the second-line aminoglycosides.
Meropenem was found to be more active than imipenem in a
recent study.30
Ertapenem has been used successfully as switch therapy for
cases treated at the hospital with meropenem who needed to be
discharged, as it can be administered once daily intramuscularly.31
If the efﬁcacy and safety proﬁle of certain drugs like linezolid,
bedaquiline, and delamanid is conﬁrmed, they might move up the
anti-TB drug hierarchy, as recently suggested.2 At present
bedaquiline and delamanid are recommended in XDR-TB or
MDR-TB cases only, when no other options are available or
tolerated.23,27
Recognizing and promptly managing possible adverse events
remains a priority, as recommended by the WHO,23,27 for the
new drugs as well as for the other second-line drugs (e.g.,
thionamides, cycloserine, and p-aminosalicylic acid, among
others).
Among the factors contributing to the programmatic success of
a given drug, the availability of the drug and of the laboratory tests
to conﬁrm susceptibility or resistance, as well as the cost-
effectiveness proﬁle, is highlighted.
Establishing a hierarchy of second-line anti-TB drugs is difﬁcult,
as we try to evaluate the effect of a single component within a
multidrug regimen where there is a lot of background noise.
3. Conclusions
In conclusion, the WHO has recently provided an important and
useful evidence-based new classiﬁcation of anti-TB drugs, which is
the present roadmap allowing clinicians to correctly design safer
and more effective MDR- and XDR-TB treatment regimens. As
more evidence becomes available, further changes are likely to
occur, particularly with the new drugs and some of the previous
group 5 drugs.tuberculosis drugs: rationale and future perspectives. Int J Infect
S. Tiberi et al. / International Journal of Infectious Diseases xxx (2017) xxx–xxx4
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IJID-2757; No. of Pages 4It is hoped that ongoing RCTs will soon provide the necessary
information to further improve the clinical and programmatic
approach to the management of MDR- and XDR-TB cases.
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